01472: Enhanced Killing of Malignant Histiocytosis with a Novel Combination of Anti-Tumor Drugs
Grant Status: Closed
The studies supported by this CHF grant sought to determine whether the combination of liposomal clodronate, a macrophage depleting agent, and CCNU, a chemotherapy drug, were more effective in treating canine malignant histiosarcoma than either agent alone. The studies found that the combination of both drugs together was not significantly more effective than either alone, though there was a trend towards better long-term survival in dogs treated with both agents. A larger study would be required to more fully address this question. Thus, there remains an unmet need for new treatments to more effectively manage MH in dogs.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.